Journal Article

In silico designing of a novel epitope-based candidate vaccine against Streptococcus pneumoniae with introduction of a new domain of PepO as adjuvant

Madanchi, Hamid, Shafaghi, Mona, Mousavi, Seyed Fazlollah, Shabani, Ali Akbar, Ranjbar, Mohammad Mehdi, Bahadori, Zohreh

2022

Overview

Background Streptococcus pneumoniae is the leading reason for invasive diseases including pneumonia and meningitis, and also secondary infections following viral respiratory diseases such as flu and COVID-19. Currently, serotype-dependent vaccines, which have several insufficiency and limitations, are the only way to prevent pneumococcal infections. Hence, it is plain to need an alternative effective strategy for prevention of this organism. Protein-based vaccine involving conserved pneumococcal protein antigens with different roles in virulence could provide an eligible alternative to existing vaccines. Methods In this study, PspC, PhtD and PsaA antigens from pneumococcus were taken to account to predict B-cell and helper T-cell epitopes, and epitope-rich regions were chosen to build the construct. To enhance the immunogenicity of the epitope-based vaccine, a truncated N-terminal fragment of pneumococcal endopeptidase O (PepO) was used as a potential TLR2/4 agonist which was identified by molecular docking studies. The ultimate construct was consisted of the chosen epitope-rich regions, along with the adjuvant role (truncated N-PepO) and suitable linkers. Results The epitope-based vaccine was assessed as regards physicochemical properties, allergenicity, antigenicity, and toxicity. The 3D structure of the engineered construct was modeled, refined, and validated. Molecular docking and simulation of molecular dynamics (MD) indicated the proper and stable interactions between the vaccine and TLR2/4 throughout the simulation periods. Conclusions For the first time this work presents a novel vaccine consisting of epitopes of PspC, PhtD, and PsaA antigens which is adjuvanted with a new truncated domain of PepO. The computational outcomes revealed that the suggested vaccine could be deemed an efficient therapeutic vaccine for S. pneumoniae ; nevertheless , in vitro and in vivo examinations should be performed to prove the potency of the candidate vaccine.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Agonists / Allergenicity / Antigenicity / Antigens / Bacterial infections / Bacterial proteins / Biomedical and Life Sciences / Biomedicine / Cloning / Computer applications / COVID-19 / Epitopes / Evaluation / Immunogenicity / Lymphocytes B / Lymphocytes T / Medical bioinformatics / Medicine/Public Health / Meningitis / Molecular dynamics / PepO / PepO gene / PhtD / Physicochemical properties / Pneumococcal vaccine / Prevention / Properties / Protein-based vaccine / PsaA / PspC / Respiratory diseases / S.pneumoniae / Streptococcus infections / Streptococcus pneumoniae / TLR2 protein / Toll-like receptors / Toxicity / Vaccines / Virulence